How long you can live with cervical cancer depends heavily on when it’s found. Across all stages combined, about 69% of women diagnosed with cervical cancer are alive five years later. But that number masks a wide range: caught early, the five-year survival rate climbs above 90%. Diagnosed after it has spread to distant organs, that figure drops to around 20%.
Survival Rates by Stage at Diagnosis
The single biggest factor in cervical cancer prognosis is how far the cancer has spread when it’s first detected. The national cancer database breaks this into three broad categories:
- Localized (cancer confined to the cervix): 91.8% five-year relative survival
- Regional (spread to nearby lymph nodes or tissues): 64.0% five-year relative survival
- Distant (spread to organs like the lungs, liver, or bones): 20.5% five-year relative survival
“Five-year relative survival” compares women with cervical cancer to women of the same age without cancer. A rate of 91.8% means women with localized disease are nearly as likely to be alive in five years as women who were never diagnosed.
More detailed staging tells a finer-grained story. Among women who had surgery for early-to-moderately-advanced cervical cancer, five-year survival ranged from about 95% for the smallest tumors (stage IB1) down to roughly 86% for larger stage IIA2 tumors. When cancer had reached pelvic lymph nodes, survival dropped to about 82%, and involvement of lymph nodes near the aorta brought it to around 56%.
The 10-Year Outlook
Most recurrences happen within the first few years, so surviving five years is a strong signal. In one study that tracked patients with operable cervical cancer for up to a decade, the overall 10-year survival was 72.5%. During that follow-up period, about 28% of patients experienced a recurrence, while the remaining 72% stayed cancer-free. If you reach the five-year mark without recurrence, the odds of long-term survival improve considerably.
What Happens If the Cancer Comes Back
Recurrence changes the picture significantly, but it doesn’t automatically mean a short timeline. In an analysis of 165 women whose cervical cancer returned after initial treatment, the median survival after recurrence was about 28 months. Around 75% were alive one year after recurrence, about 42% at three years, and roughly 32% at five years. Where and how the cancer returns matters: a small, localized recurrence in the pelvis often has more treatment options than widespread disease.
Metastatic Cervical Cancer
When cervical cancer is diagnosed at or progresses to stage IVB, meaning it has spread to distant sites, the median survival has historically been 8 to 13 months with standard chemotherapy alone. That timeline has been shifting with newer treatments.
Adding a targeted therapy that cuts off blood supply to tumors extended median survival by nearly four months in clinical trials. More recently, combining immunotherapy with chemotherapy produced a more dramatic jump. In the landmark KEYNOTE-826 trial, women with advanced cervical cancer who received immunotherapy alongside chemotherapy had a median overall survival of 28.6 months, compared to 16.5 months with chemotherapy alone. That’s a difference of roughly a year, and it represents one of the most meaningful advances in treatment for this group of patients.
How Age Affects Prognosis
Younger women generally fare better, and the gap is most pronounced in later-stage disease. For women diagnosed with late-stage cervical cancer in their 20s and 30s, the five-year relative survival was about 51.5%. For those in their 40s and 50s, it was around 47.5%. The decline becomes steeper after 65: women aged 65 to 69 had a five-year survival of 36.8%, and for those 80 and older, it dropped to 23.2%.
Several factors drive this difference. Older women are less likely to tolerate aggressive treatment regimens, more likely to have other health conditions that complicate care, and sometimes diagnosed at more advanced stages because they’ve stopped getting routine screenings.
Cell Type and Other Factors
About 70% of cervical cancers are squamous cell carcinomas, and most of the rest are adenocarcinomas. There’s a long-standing question about whether one type carries a worse prognosis. When researchers compared the two after matching patients by age, stage, and treatment, the five-year survival rates were very similar: about 75% for squamous cell carcinoma and 72% for adenocarcinoma. The cell type alone is not a major driver of survival when other factors are comparable.
Beyond staging and cell type, other factors that influence how long someone lives with cervical cancer include tumor size, whether cancer cells are found in blood or lymph vessels, how deeply the tumor has invaded surrounding tissue, and how well the cancer responds to initial treatment. Women whose tumors shrink completely after radiation and chemotherapy have a significantly better long-term outlook than those with residual disease.
What These Numbers Mean for You
Survival statistics describe large groups of women diagnosed over previous years. They reflect a mix of ages, health conditions, treatment approaches, and access to care. Your individual prognosis could be better or worse than the averages depending on those variables. The statistics also lag behind treatment advances. The immunotherapy results now being incorporated into standard care were not reflected in the five-year survival data collected even a few years ago, meaning current outcomes for advanced disease are likely improving beyond what published numbers show.
What the data makes clear is that early detection remains the most powerful predictor of long-term survival. A localized cervical cancer found through routine screening carries a prognosis close to that of women without cancer. Even for advanced and recurrent disease, treatment options have expanded meaningfully in the past several years, pushing median survival timelines longer than they’ve ever been.